ConductScience.org, home
Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia
API referenceFor AI assistants

Trial · NCT02075463

Results by group148

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 148

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Percentage of Participants Demonstrating an Increase in Hgb of >=1 g/dL (if Baseline Hgb is <9.5 g/dL), or >=0.5 g/dL (if Baseline Hgb is 9.5-<10 g/dL), or Stay Within Target Range and do Not Drop by >0.5 g/dL (if Baseline Hgb is >= 10 g/dL) at Week 16
GSK1278863 12 mg QD28.695% Confidence Interval 8.2 to 64.1Percentage of participants
Change From Baseline in Hgb Levels at Week 16GSK1278863 12 mg QD0.10Standard Deviation 1.319g/dL
Percentage of Time (Days) Hgb Levels Within, Below and Above Target Range at the Indicated Time PointGSK1278863 12 mg QDWithin Target Range48.28Standard Deviation 46.102Percentage of days
Percentage of Time (Days) Hgb Levels Within, Below and Above Target Range at the Indicated Time PointGSK1278863 12 mg QDAbove target range0.92Standard Deviation 2.605Percentage of days
Percentage of Time (Days) Hgb Levels Within, Below and Above Target Range at the Indicated Time PointGSK1278863 12 mg QDBelow target range50.80Standard Deviation 47.176Percentage of days
Number of Participants Achieving at Least 1 g/dL Increase in Hgb From Baseline at Week 16GSK1278863 12 mg QD2Participants
Number of Participants With Hgb in the Target Range at Week 16GSK1278863 12 mg QD2Participants
Number of Participants Reaching Pre-defined Hgb Stopping CriteriaGSK1278863 12 mg QD3Participants
Percent Change From Baseline in Hepcidin at Week 16GSK1278863 12 mg QD16.4995% Confidence Interval -12.14 to 54.43Percent change in hepcidin
Change From Baseline in Ferritin at Week 16GSK1278863 12 mg QD-72.1Standard Deviation 134.81Micrograms/Liter
Change From Baseline in Transferrin at Week 16GSK1278863 12 mg QD0.080Standard Deviation 0.2332Percent change
Percent Change From Baseline in Transferrin Saturation at Week 16GSK1278863 12 mg QD18.595% Confidence Interval -21.4 to 78.8Percent change in transferrin
Change From Baseline in Total Iron at Week 16GSK1278863 12 mg QDParticipant 14Micromoles (µmol)/L
Change From Baseline in Total Iron at Week 16GSK1278863 12 mg QDParticipant 221Micromoles (µmol)/L
Change From Baseline in Total Iron at Week 16GSK1278863 12 mg QDParticipant 3-3Micromoles (µmol)/L
Change From Baseline in Total Iron at Week 16GSK1278863 12 mg QDParticipant 43Micromoles (µmol)/L
Change From Baseline in Total Iron at Week 16GSK1278863 12 mg QDParticipant 52Micromoles (µmol)/L
Change From Baseline in Total Iron at Week 16GSK1278863 12 mg QDParticipant 65Micromoles (µmol)/L
Change From Baseline in Total Iron at Week 16GSK1278863 12 mg QDParticipant 7-5Micromoles (µmol)/L
Change From Baseline in Total Iron Binding Capacity (TIBC) at Week 16GSK1278863 12 mg QDParticipant 114µmol/ L

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02075463/results

API referenceFor AI assistants